HK Stock Movement | INNOGEN-B (02591) Rises Over 3% Intraday as Esupaglutide α Recommended in National Diabetes Prevention Guidelines

Stock News12-17

INNOGEN-B (02591) surged over 3% intraday, reaching a 3.43% gain at press time to HK$32, with a turnover of HK$20.74 million. The company announced via its official WeChat account that Esupaglutide α (brand name: Yinuoqing®), China's first domestically developed ultra-long-acting human GLP-1 receptor agonist (GLP-1RA), has been included in the 2025 National Reimbursement Drug List for "blood glucose control in adult type 2 diabetes patients," effective January 1, 2026. This marks a significant step in expanding access to innovative diabetes treatments in China.

The National Primary Diabetes Prevention and Management Guidelines (2025) listed Esupaglutide α as a weekly GLP-1RA injectable, providing policy and regulatory support for its use in primary healthcare institutions. The guidelines highlight GLP-1RA as a key treatment option for adult type 2 diabetes (T2DM) patients with atherosclerotic cardiovascular disease (ASCVD) or its risk factors, heart failure, chronic kidney disease (CKD), as well as overweight or obese patients requiring weight management.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1125323298?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-17 11:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1125323298","market":"sh","top_or_hot":-1,"title":"HK Stock Movement | INNOGEN-B (02591) Rises Over 3% Intraday as Esupaglutide α Recommended in National Diabetes Prevention Guidelines","media":"Stock News","content":"<p>INNOGEN-B (02591) surged over 3% intraday, reaching a 3.43% gain at press time to HK$32, with a turnover of HK$20.74 million. The company announced via its official WeChat account that Esupaglutide α (brand name: Yinuoqing®), China's first domestically developed ultra-long-acting human GLP-1 receptor agonist (GLP-1RA), has been included in the 2025 National Reimbursement Drug List for \"blood glucose control in adult type 2 diabetes patients,\" effective January 1, 2026. This marks a significant step in expanding access to innovative diabetes treatments in China.</p>\n<p>The National Primary Diabetes Prevention and Management Guidelines (2025) listed Esupaglutide α as a weekly GLP-1RA injectable, providing policy and regulatory support for its use in primary healthcare institutions. The guidelines highlight GLP-1RA as a key treatment option for adult type 2 diabetes (T2DM) patients with atherosclerotic cardiovascular disease (ASCVD) or its risk factors, heart failure, chronic kidney disease (CKD), as well as overweight or obese patients requiring weight management.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HK Stock Movement | INNOGEN-B (02591) Rises Over 3% Intraday as Esupaglutide α Recommended in National Diabetes Prevention Guidelines</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHK Stock Movement | INNOGEN-B (02591) Rises Over 3% Intraday as Esupaglutide α Recommended in National Diabetes Prevention Guidelines\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-12-17 11:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>INNOGEN-B (02591) surged over 3% intraday, reaching a 3.43% gain at press time to HK$32, with a turnover of HK$20.74 million. The company announced via its official WeChat account that Esupaglutide α (brand name: Yinuoqing®), China's first domestically developed ultra-long-acting human GLP-1 receptor agonist (GLP-1RA), has been included in the 2025 National Reimbursement Drug List for \"blood glucose control in adult type 2 diabetes patients,\" effective January 1, 2026. This marks a significant step in expanding access to innovative diabetes treatments in China.</p>\n<p>The National Primary Diabetes Prevention and Management Guidelines (2025) listed Esupaglutide α as a weekly GLP-1RA injectable, providing policy and regulatory support for its use in primary healthcare institutions. The guidelines highlight GLP-1RA as a key treatment option for adult type 2 diabetes (T2DM) patients with atherosclerotic cardiovascular disease (ASCVD) or its risk factors, heart failure, chronic kidney disease (CKD), as well as overweight or obese patients requiring weight management.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"","article_id":"1125323298","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1125323298","pubTimestamp":1765940775,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"INNOGEN-B (02591) surged over 3% intraday, reaching a 3.43% gain at press time to HK$32, with a turnover of HK$20.74 million. The company announced via its official WeChat account that Esupaglutide α...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","02591":"银诺医药－Ｂ"},"translate_title":"港股动向|英诺健-B(02591)盘中涨超3%获国家糖尿病防治指南推荐依苏帕鲁肽α","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02591":1},"content_text":"INNOGEN-B (02591) surged over 3% intraday, reaching a 3.43% gain at press time to HK$32, with a turnover of HK$20.74 million. The company announced via its official WeChat account that Esupaglutide α (brand name: Yinuoqing®), China's first domestically developed ultra-long-acting human GLP-1 receptor agonist (GLP-1RA), has been included in the 2025 National Reimbursement Drug List for \"blood glucose control in adult type 2 diabetes patients,\" effective January 1, 2026. This marks a significant step in expanding access to innovative diabetes treatments in China.\nThe National Primary Diabetes Prevention and Management Guidelines (2025) listed Esupaglutide α as a weekly GLP-1RA injectable, providing policy and regulatory support for its use in primary healthcare institutions. The guidelines highlight GLP-1RA as a key treatment option for adult type 2 diabetes (T2DM) patients with atherosclerotic cardiovascular disease (ASCVD) or its risk factors, heart failure, chronic kidney disease (CKD), as well as overweight or obese patients requiring weight management.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1125323298","isCrawlerRequest":true}